AMGN

Closing Bell for Wednesday on Wall Street: Markets Open Lower, Stock Prices Rise All Day

24/7 Wall St. Closing Bell — Wednesday: Markets Cannot Shake-off Low Open and Sink to Close

Pfizer Earnings Miss Follows Amgen: Is Merck Next?

Daily ETF Folly: Why There Is No True Biotech Representation in ETFs

Strange Stock Trends in the Fidelity Contrafund (WFC, JPM, IRE, KO, PEP, BRK-A, BIIB, AMGN, AAPL, GOOG, INTC, MSFT, XOM, CVX)

Top Analyst Upgrades and Downgrades (AMGN, AOL, BBVA, BEBE, SCHW, CLGX, ELN, HIG, KR, NKE, SIAL, TSO, USAC, USB, VMW, WFC)

JMP Securities Very Positive on Five Key Biotech Stocks (AMGN, BIIB, AFFY, ALNY, CELG, ONXX, PCYC, PFE, LLY, MRK, BMY)

24/7 Wall St. Closing Bell — January 25, 2013: Markets Open Higher, S&P Closes Over 1,500 (JNS, AMZN, AMGN, AAPL, EBAY, T, JNPR, MSFT, SBUX, HAL, HON, KMB, WY, CAT, ROP, SIFY, BIIB, NFLX, BFAM, SCSS)

Top Analyst Upgrades and Downgrades (ATK, AMZN, AMCX, AMGN, AAPL, ADSK, EBAY, FLEX, JNS, ORCL, TIF, WPRT, GS, JPM, UBS)

24/7 Wall St. Closing Bell — January 24, 2013: Markets Mixed After Apple Earnings (AAPL, PG, EMR, CVS, GOLD, TIF, AMGN, SNDK, FFIV, NE, NVR, WDC, MMM, BMY, LMT, RTN, LUV, UNP, UAL, XRX, T, JNPR, MSFT, SBUX, HAL, HON, KMB, WY, NOK, NFLX, SWFT)

24/7 Wall St. Closing Bell — January 23, 2013: Market Open Higher on Little News (COST, GE, VZ, F, INCY, AMD, CSX, GOOG, IBM, IGT, TXN, ABT, BHI, COH, GD, MCD, LCC, AAPL, AMGN, NFLX, SNDK, FFIV, NE, NVR, WDC, MMM, BMY, LMT, RYN, LUV, UNP, UAL, XRX, M

Earnings Preview for Today: AMGN, AAPL, NFLX, SNDK

Repurchase Mania: The Top 10 Buyback Stocks

When IBM raised its buyback authorization by $10 billion on Oct. 26, it was the 259th company to announce repurchase plans in October alone. Citi Investment Research says a long-term trend of rising buybacks has only just begun.

Big pharma heats up with high performance for drugs, earnings

The Daily Blogwatch: Is Facebook cash-flow positive? Is AMGN a homerun?

New drug helps prevent osteoporosis, but the downside could be cancer

Amgen jumps 15 percent on results of clinical trial

Pharma Report: New drugs coming, but what about Pfizer?

Amgen misses as drug sales decline, looking at denosumab for growth